221 related articles for article (PubMed ID: 30608393)
21. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
[TBL] [Abstract][Full Text] [Related]
22. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
Chiang HH; Lee CM; Hu TH; Hung CH; Wang JH; Lu SN; Lai HC; Su WP; Lin CH; Peng CY; Chen CH
Liver Int; 2018 Nov; 38(11):1997-2005. PubMed ID: 29797410
[TBL] [Abstract][Full Text] [Related]
23. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
24. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
[TBL] [Abstract][Full Text] [Related]
26. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
[TBL] [Abstract][Full Text] [Related]
27. Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.
Loglio A; Iavarone M; Viganò M; Orenti A; Facchetti F; Cortinovis I; Lunghi G; Ceriotti F; Occhipinti V; Rumi M; Sangiovanni A; Colombo M; Lampertico P
Liver Int; 2019 Oct; 39(10):1964-1974. PubMed ID: 31323159
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
[TBL] [Abstract][Full Text] [Related]
29. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
[TBL] [Abstract][Full Text] [Related]
30. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
Papatheodoridis GV; Idilman R; Dalekos GN; Buti M; Chi H; van Boemmel F; Calleja JL; Sypsa V; Goulis J; Manolakopoulos S; Loglio A; Siakavellas S; Keskın O; Gatselis N; Hansen BE; Lehretz M; de la Revilla J; Savvidou S; Kourikou A; Vlachogiannakos I; Galanis K; Yurdaydin C; Berg T; Colombo M; Esteban R; Janssen HLA; Lampertico P
Hepatology; 2017 Nov; 66(5):1444-1453. PubMed ID: 28622419
[TBL] [Abstract][Full Text] [Related]
31. Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Hui VW; Yip TC; Wong VW; Tse YK; Chan HL; Lui GC; Wong GL
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00324. PubMed ID: 33750746
[TBL] [Abstract][Full Text] [Related]
32. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
33. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
[TBL] [Abstract][Full Text] [Related]
34. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Yakushijin T; Iio S; Doi Y; Yamada A; Kaneko A; Hagiwara H; Mita E; Oshita M; Itoh T; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
J Gastroenterol; 2015 Jul; 50(7):785-94. PubMed ID: 25384794
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
[TBL] [Abstract][Full Text] [Related]
36. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
[TBL] [Abstract][Full Text] [Related]
37. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Lin CC; Bair MJ; Chen CJ; Lee KH; Chen MJ; Liu CY; Chang CW; Hu KC; Liou TC; Lin SC; Wang HY; Chu CH; Shih SC; Wang TE
Kaohsiung J Med Sci; 2016 Jan; 32(1):10-5. PubMed ID: 26853169
[TBL] [Abstract][Full Text] [Related]
38. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients.
Sou FM; Hu TH; Hung CH; Lai HC; Wang JH; Lu SN; Peng CY; Chen CH
Hepatol Int; 2020 Jul; 14(4):513-520. PubMed ID: 32319045
[TBL] [Abstract][Full Text] [Related]
39. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.
Vlachogiannakos J; Papatheodoridis G
World J Gastroenterol; 2013 Dec; 19(47):8822-30. PubMed ID: 24379605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
